Press "Enter" to skip to content

Moderna increases minority numbers in its vaccine trial, but still not meeting Fauci’s goal

Moderna, the first US company to begin Phase 3 clinical trials of a coronavirus vaccine in the US, increased its enrollment of minorities this week, but is still not even close to the levels requested by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

cnn topstories?d=yIl2AUoC8zA cnn topstories?d=7Q72WNTAKBA cnn topstories?i=JlyFjKt31OA:d5hrD3Em0S8:V sGLiPBpWU cnn topstories?d=qj6IDK7rITs cnn topstories?i=JlyFjKt31OA:d5hrD3Em0S8:gIN9vFwOqvQ

JlyFjKt31OA
Moderna, the first US company to begin Phase 3 clinical trials of a coronavirus vaccine in the US, increased its enrollment of minorities this week, but is still not even close to the levels requested by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *